Stock Analysis
Formosa Laboratories First Quarter 2024 Earnings: NT$0.80 loss per share (vs NT$0.21 loss in 1Q 2023)
Formosa Laboratories (TWSE:4746) First Quarter 2024 Results
Key Financial Results
- Revenue: NT$1.13b (up 22% from 1Q 2023).
- Net loss: NT$96.0m (loss widened by 282% from 1Q 2023).
- NT$0.80 loss per share (further deteriorated from NT$0.21 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Formosa Laboratories Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 37% growth forecast for the Pharmaceuticals industry in Taiwan.
Performance of the Taiwanese Pharmaceuticals industry.
The company's shares are up 2.9% from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for Formosa Laboratories that we have uncovered.
Valuation is complex, but we're helping make it simple.
Find out whether Formosa Laboratories is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:4746
Formosa Laboratories
Engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers worldwide.
Flawless balance sheet and undervalued.